<?xml version="1.0" encoding="UTF-8"?>
<results title="tropicalVirus">
 <result pre="CentralLondon pmcid: 72164175042 doi: 10.1186/s12879-020-05042-2 : Research Article Prevalence of" exact="Zika" post="virus neutralizing antibodies in healthy adults in Vietnam during"/>
 <result pre="antibodies in healthy adults in Vietnam during and after the" exact="Zika" post="virus epidemic season: a longitudinal population-based survey NguyenCo Thach123MoiMeng"/>
 <result pre="data. Abstract Background Between 2016 and 2019, 265 cases of" exact="Zika" post="virus (ZIKV) infection were reported in Vietnam, predominantly in"/>
 <result pre="The study aims to determine the level of immunity to" exact="ZIKV" post="in the general population of the ZIKV epidemic region."/>
 <result pre="of immunity to ZIKV in the general population of the" exact="ZIKV" post="epidemic region. Methods A total of 879 serum samples"/>
 <result pre="between January 2017 and July 2018, during and after the" exact="ZIKV" post="epidemic in Vietnam. The samples were tested for anti-ZIKV"/>
 <result pre="using enzyme-linked immunosorbent assays (ELISA). Plaque-reduction neutralization test (PRNT) for" exact="ZIKV" post="was performed on all samples, and for DENV on"/>
 <result pre="(PRNT) for ZIKV was performed on all samples, and for" exact="DENV" post="on the samples that ZIKV neutralizing antibody positive. Results"/>
 <result pre="on all samples, and for DENV on the samples that" exact="ZIKV" post="neutralizing antibody positive. Results A total of 83 (10.3%)"/>
 <result pre="anti-ZIKV IgM. Of the 83, 6 were confirmed to be" exact="ZIKV" post="antibodies positive using PRNT and anti-ZIKV IgG ELISA. Of"/>
 <result pre="positive for antibodies against ZIKV. Of the 9 participants with" exact="ZIKV" post="infection, 5 lived in the same village as the"/>
 <result pre="2 neighboring communes. Repeat samples were collected from the 83" exact="ZIKV" post="IgM positive participants 1.5 years after the first collection. No"/>
 <result pre="participants 1.5 years after the first collection. No new cases of" exact="ZIKV" post="infection were detected. In addition, 2 of 3 participants"/>
 <result pre="anti-ZIKV NS1 IgG demonstrated a 4- to 8-fold increase in" exact="ZIKV" post="neutralizing antibody titer. Conclusions ZIKV was present in the"/>
 <result pre="4- to 8-fold increase in ZIKV neutralizing antibody titer. Conclusions" exact="ZIKV" post="was present in the area around Krong Buk, with"/>
 <result pre="results also reflect on low levels of protective immunity to" exact="Zika" post="within the population. These results provide a better understanding"/>
 <result pre="population. These results provide a better understanding of the current" exact="ZIKV" post="epidemic status in the region and demonstrate a need"/>
 <result pre="region and demonstrate a need for implementation of more effective" exact="ZIKV" post="infection control measures. Keywords Zika virus Zika virus infection"/>
 <result pre="for implementation of more effective ZIKV infection control measures. Keywords" exact="Zika" post="virus Zika virus infection Seroprevalence Seroepidemiologic studies Neutralizing antibodies"/>
 <result pre="of more effective ZIKV infection control measures. Keywords Zika virus" exact="Zika" post="virus infection Seroprevalence Seroepidemiologic studies Neutralizing antibodies Vietnam Funding"/>
 <result pre="Funding Japan Agency for Medical Research and Development (JP)JP20wm0125006 Background" exact="Zika" post="virus (ZIKV) was first isolated from Rhesus monkeys in"/>
 <result pre="virus (ZIKV) was first isolated from Rhesus monkeys in the" exact="Zika" post="forest in Uganda in 1947 [1]. It is a"/>
 <result pre="bite of infected Aedes aegepti and Aedes albopictus mosquitoes [3]." exact="ZIKV" post="can also be transmitted through sexual intercourse or body"/>
 <result pre="Common symptoms are rash, fever, arthralgia, and conjunctivitis [5]. While" exact="ZIKV" post="infection is sometimes associated with only mild symptoms, it"/>
 <result pre="syndrome [6] and microcephaly in infants [7]. The first reported" exact="ZIKV" post="epidemic occurred in Yap Island, Federated States of Micronesia,"/>
 <result pre="of infants born with microcephaly suspected to be associated with" exact="ZIKV" post="[7, 10]. According to a July 2019 WHO report"/>
 <result pre="a July 2019 WHO report there has been evidence of" exact="ZIKV" post="transmission in 87 countries and territories in the Americas,"/>
 <result pre="region [11]. While Southeast Asia has been known as a" exact="ZIKV" post="endemic region for more than 60 years, large ZIKV epidemics"/>
 <result pre="as a ZIKV endemic region for more than 60 years, large" exact="ZIKV" post="epidemics has only been reported recently [12]. Although the"/>
 <result pre="from 2015 to 2017 [15]. During this period, cases of" exact="ZIKV" post="infection were also reported in other Southeast Asia nations"/>
 <result pre="Myanmar [17]. In 2016, 3 tourists were confirmed to have" exact="ZIKV" post="infection after visiting Vietnam [18–20]. As of June 2019,"/>
 <result pre="5 family members and 2 neighbors were confirmed positive for" exact="ZIKV" post="infection [25]. Despite the endemicity for dengue and the"/>
 <result pre="high density of mosquito vectors, the numbers of cases of" exact="ZIKV" post="infection in Vietnam remain substantially lower than the number"/>
 <result pre="Aedes aegypti mosquitoes are endemic. While neighboring areas have reported" exact="ZIKV" post="outbreaks in recent years, there are limited data available"/>
 <result pre="years, there are limited data available on the extent of" exact="ZIKV" post="infection in local populations in Vietnam. Additionally, it has"/>
 <result pre="to cross-reactive immunity toward ZIKV, thus limiting the size of" exact="ZIKV" post="epidemics in Southeast Asia. However, there were limited seroprevalence"/>
 <result pre="were limited seroprevalence data to support this hypothesis. Cross-reactivity between" exact="ZIKV" post="and DENV antibodies has led to difficulties in the"/>
 <result pre="seroprevalence data to support this hypothesis. Cross-reactivity between ZIKV and" exact="DENV" post="antibodies has led to difficulties in the interpretation in"/>
 <result pre="population being seropositive [28]. Recent studies have suggested that while" exact="DENV" post="is cross-reactive with ZIKV, the level of cross-neutralization and"/>
 <result pre="disease protection is limited [29–31]. In Vietnam, the number of" exact="ZIKV" post="infections peaked at 219 in 2016, and has subsequently"/>
 <result pre="purpose of this study was to determine the seroprevalence of" exact="ZIKV" post="antibodies among the population in Vietnam during and after"/>
 <result pre="among the population in Vietnam during and after the 2016" exact="Zika" post="epidemic using ZIKV and DENV neutralizing assays to elucidate"/>
 <result pre="in Vietnam during and after the 2016 Zika epidemic using" exact="ZIKV" post="and DENV neutralizing assays to elucidate the extent of"/>
 <result pre="during and after the 2016 Zika epidemic using ZIKV and" exact="DENV" post="neutralizing assays to elucidate the extent of the ZIKV"/>
 <result pre="and DENV neutralizing assays to elucidate the extent of the" exact="ZIKV" post="epidemic in the local population. Methods Ethics approval and"/>
 <result pre="In this study, we estimated the proportion of persons with" exact="ZIKV" post="infection in Krong Buk District. The required sample size"/>
 <result pre="of collection and stored at − 80 °C prior to testing. In-house" exact="Zika" post="virus immunoglobulin M enzyme-linked immunosorbent assay The samples were"/>
 <result pre="immunoglobulin M enzyme-linked immunosorbent assay The samples were screened for" exact="ZIKV" post="IgM using an in-house ZIKV IgM ELISA kit. This"/>
 <result pre="The samples were screened for ZIKV IgM using an in-house" exact="ZIKV" post="IgM ELISA kit. This method was adapted from Dengue"/>
 <result pre="in-house ZIKV IgM ELISA kit. This method was adapted from" exact="Dengue" post="Virus IgM Capture DxSelect (Focus Diagnostics, Cypress, CA, USA)"/>
 <result pre="Capture DxSelect (Focus Diagnostics, Cypress, CA, USA) [34] by replacing" exact="DENV" post="antigen with ZIKV antigen. The modified in-house ZIKV IgM"/>
 <result pre="Diagnostics, Cypress, CA, USA) [34] by replacing DENV antigen with" exact="ZIKV" post="antigen. The modified in-house ZIKV IgM ELISA has been"/>
 <result pre="by replacing DENV antigen with ZIKV antigen. The modified in-house" exact="ZIKV" post="IgM ELISA has been utilized in other studies [25,"/>
 <result pre="3 times with 1X wash buffer solution. Next, 100 μL of" exact="ZIKV" post="antigen (MR-766, 105 PFU/mL) was added and incubated at"/>
 <result pre="dengue virus immunoglobulins M and G (IgM and IgG), and" exact="Zika" post="virus immunoglobulin-G by enzyme-linked immunosorbent assay (ELISA) In addition"/>
 <result pre="samples that exhibited anti-ZIKV IgM antibodies and neutralizing antibodies to" exact="ZIKV" post="according to manufacturer’s instructions. OD values which were ≥ 2 times"/>
 <result pre="samples were screened for the presence of neutralizing antibodies to" exact="ZIKV" post="using a plaque-reduction neutralization test (PRNT). Serum samples were"/>
 <result pre="(1:10–1:10240). The PRNT was performed in replicates of 2 for" exact="ZIKV" post="(MR766 laboratory strain) and all 4 DENV serotypes (DENV-1"/>
 <result pre="of 2 for ZIKV (MR766 laboratory strain) and all 4" exact="DENV" post="serotypes (DENV-1 01–44 strain; DENV-2 TLC-30 strain; DENV-3 CH53469"/>
 <result pre="90% respectively. The presence of neutralizing antibodies was defined as" exact="ZIKV" post="PRNT50 titer ≥20. The criteria to confirm the case"/>
 <result pre="titer ≥20. The criteria to confirm the case exposed to" exact="ZIKV" post="that has neutralizing antibodies to ZIKV with PRNT50 titer"/>
 <result pre="the case exposed to ZIKV that has neutralizing antibodies to" exact="ZIKV" post="with PRNT50 titer ≥20, and 4 fold higher compare"/>
 <result pre="with PRNT50 titer ≥20, and 4 fold higher compare to" exact="DENV" post="titers. The interpretation of probable ZIKV infection was according"/>
 <result pre="fold higher compare to DENV titers. The interpretation of probable" exact="ZIKV" post="infection was according to WHO guidelines for laboratory testing"/>
 <result pre="infection was according to WHO guidelines for laboratory testing for" exact="Zika" post="virus infection in which samples that were positive for"/>
 <result pre="Zika virus infection in which samples that were positive for" exact="ZIKV" post="IgM and negative for DENV IgM was interpreted as"/>
 <result pre="samples that were positive for ZIKV IgM and negative for" exact="DENV" post="IgM was interpreted as ZIKV probable case [37]. Data"/>
 <result pre="ZIKV IgM and negative for DENV IgM was interpreted as" exact="ZIKV" post="probable case [37]. Data analysis Descriptive analyses were performed,"/>
 <result pre="intervals (CIs) were used to estimate the relative likelihood of" exact="ZIKV" post="infection in each group. Multiple logistic regression was used"/>
 <result pre="assess the association of sex, ethnicity, and age group with" exact="ZIKV" post="infection. The analyses were performed using Stata 14.1 (StataCorp"/>
 <result pre="pregnant women who participated in this study was 66 (8.24%)." exact="Zika" post="virus and dengue seroprevalence Of the 801 samples tested,"/>
 <result pre="the 46–60 year age group (14.2%) (Fig. 1(a)). The seroprevalence of" exact="ZIKV" post="IgM did not differ significantly according to sex or"/>
 <result pre="1 Demographic characteristics of the study participants (N = 801) Variables n" exact="ZIKV" post="IgM positive (%) Crude OR (95% CI) P-value DENV"/>
 <result pre="n ZIKV IgM positive (%) Crude OR (95% CI) P-value" exact="DENV" post="IgG positive (%) (n = 83) Anti-ZIKV NS1 IgG positive"/>
 <result pre="Anti-ZIKV NS1 IgG positive (%) (n = 88) PRNT50 positive to" exact="ZIKV" post="(%) Age group (years) ≤15 87 11 (12.6) 1.00"/>
 <result pre="66 1 (1.5) 0/1(0.0) 0/1(0.0) 0/66 (0.0) CI confidence interval," exact="DENV" post="dengue virus, IgG immunoglobulin G, IgM immunoglobulin M, NA"/>
 <result pre="G, IgM immunoglobulin M, NA not available, OR odds ratio," exact="ZIKV" post="Zika virus, ssIKV NS1 IgG positive, ZIKV antibodies were"/>
 <result pre="IgM immunoglobulin M, NA not available, OR odds ratio, ZIKV" exact="Zika" post="virus, ssIKV NS1 IgG positive, ZIKV antibodies were determined"/>
 <result pre="OR odds ratio, ZIKV Zika virus, ssIKV NS1 IgG positive," exact="ZIKV" post="antibodies were determined using anti-ZIKV NS1 IgG ELISA (P/N"/>
 <result pre="using anti-ZIKV NS1 IgG ELISA (P/N ratio ≥ 2); PRNT50 positive to" exact="ZIKV" post="was defined as plaque-reduction neutralization test titers with a ≥ 50%"/>
 <result pre="defined as plaque-reduction neutralization test titers with a ≥ 50% reduction in" exact="ZIKV" post="plaque-forming units at a serum dilution of ≥1:20 a"/>
 <result pre="in the multivariate logistic regression analysis Fig. 1 Seroprevalence of" exact="Zika" post="virus (ZIKV) antibodies in Central Vietnam, 2017–2018. The seroprevalence"/>
 <result pre="virus (ZIKV) antibodies in Central Vietnam, 2017–2018. The seroprevalence of" exact="Zika" post="virus antibodies according to (a) age and (b) ethnicity."/>
 <result pre="anti-ZIKV IgM antibodies as determined by using enzyme-linked immunosorbent assays." exact="ZIKV" post="neutralizing antibodies was determined by using plaque-reduction neutralization test"/>
 <result pre="83 samples and 88 samples, respectively All 83 participants with" exact="ZIKV" post="anti-IgM antibodies were negative for dengue IgM on ELISA;"/>
 <result pre="were negative for dengue IgM on ELISA; however, 49 (59.0%)" exact="ZIKV" post="IgM positive cases were detected as positive for Dengue"/>
 <result pre="(59.0%) ZIKV IgM positive cases were detected as positive for" exact="Dengue" post="IgG ELISA (Table 1). DENV IgM and DENV IgG"/>
 <result pre="were detected as positive for Dengue IgG ELISA (Table 1)." exact="DENV" post="IgM and DENV IgG antibodies was determined to examine"/>
 <result pre="positive for Dengue IgG ELISA (Table 1). DENV IgM and" exact="DENV" post="IgG antibodies was determined to examine possible cross-reactivity to"/>
 <result pre="DENV IgG antibodies was determined to examine possible cross-reactivity to" exact="ZIKV" post="infection. The distribution of the ZIKV IgM antibodies positive"/>
 <result pre="examine possible cross-reactivity to ZIKV infection. The distribution of the" exact="ZIKV" post="IgM antibodies positive cases, as well as DENV IgG"/>
 <result pre="of the ZIKV IgM antibodies positive cases, as well as" exact="DENV" post="IgG antibodies positive cases, was observed in all age"/>
 <result pre="minority Ede ethnic group (Fig. 1b). Neutralizing antibody levels to" exact="Zika" post="virus and dengue virus serotypes 1–4 All 801 samples"/>
 <result pre="the presence of neutralizing antibodies to ZIKV. Of the 83" exact="ZIKV" post="IgM-positive samples, 8 demonstrated neutralizing antibodies to ZIKV (PRNT50 = 1:"/>
 <result pre="the 83 ZIKV IgM-positive samples, 8 demonstrated neutralizing antibodies to" exact="ZIKV" post="(PRNT50 = 1: 40 to 1: 640). Of the 8 samples,"/>
 <result pre="640). Of the 8 samples, 3 (Z141a, Z153a, Z735a) exhibited" exact="ZIKV" post="antibody titers that were &amp;gt; 4-fold higher than the antibody titers"/>
 <result pre="that were &amp;gt; 4-fold higher than the antibody titers for all 4" exact="DENV" post="serotypes (PRNT50 ZIKV = 1: 160 to 1: 640) (Table 2)."/>
 <result pre="samples (Z120a, Z138a, Z140a, Z420a, Z476a) were classified as probable" exact="ZIKV" post="infections (PRNT50 ZIKV = 1: 40–1: 640). Table 2 Anti-Zika virus"/>
 <result pre="and G levels of 13 participants with neutralizing antibodies to" exact="Zika" post="virus epidemic) (N = 879) ELISA results Neutralizing antibody titer (PRNT50)"/>
 <result pre="Neutralizing antibody titer (PRNT50) Neutralizing antibody titer (PRNT90) Sample ID" exact="ZIKV" post="IgM(P/N ratio) DENV IgM(Index Value) Anti-ZIKVNS1 IgG (P/N ratio)"/>
 <result pre="(PRNT50) Neutralizing antibody titer (PRNT90) Sample ID ZIKV IgM(P/N ratio)" exact="DENV" post="IgM(Index Value) Anti-ZIKVNS1 IgG (P/N ratio) ZIKV DENV-1 DENV-2"/>
 <result pre="ZIKV IgM(P/N ratio) DENV IgM(Index Value) Anti-ZIKVNS1 IgG (P/N ratio)" exact="ZIKV" post="DENV-1 DENV-2 DENV-3 DENV-4 ZIKV DENV-1 DENV-2 DENV-3 DENV-4"/>
 <result pre="Value) Anti-ZIKVNS1 IgG (P/N ratio) ZIKV DENV-1 DENV-2 DENV-3 DENV-4" exact="ZIKV" post="DENV-1 DENV-2 DENV-3 DENV-4 During epidemic (January 2017) Z120aa"/>
 <result pre="80 40 &amp;lt; 20 40 &amp;lt; 20 &amp;lt; 20 20 &amp;lt; 20 20 &amp;lt; 20" exact="DENV" post="dengue virus, DENV1–4 dengue virus serotypes 1–4, ELISA enzyme-linked"/>
 <result pre="neutralization defined as ≥90% reduction in challenge virus plaque-forming units," exact="ZIKV" post="Zika virus Figures in bold indicate positive results.a ZIKV"/>
 <result pre="defined as ≥90% reduction in challenge virus plaque-forming units, ZIKV" exact="Zika" post="virus Figures in bold indicate positive results.a ZIKV antibodies"/>
 <result pre="units, ZIKV Zika virus Figures in bold indicate positive results.a" exact="ZIKV" post="antibodies were determined using anti-ZIKV NS1 IgG ELISA (P/N"/>
 <result pre="including two (Z153 and Z420) of the 8 participants with" exact="ZIKV" post="neutralizing antibodies in their initial sample. Two participants (Z120"/>
 <result pre="and Z476) experienced a 4- to 8-fold increase in their" exact="ZIKV" post="neutralizing antibody titers (Table 2). Of the 83 participants"/>
 <result pre="antibodies, 5 (6.0%; Z140, Z141, Z153, Z476 and Z735) had" exact="ZIKV" post="neutralizing antibody titers that were at least 4-fold greater"/>
 <result pre="least 4-fold greater than their antibody titers against the 4" exact="DENV" post="serotypes tested. Of the 718 samples that were negative"/>
 <result pre="(Z147a, Z472a, Z606a, Z587a and Z591a) demonstrated neutralizing antibodies to" exact="ZIKV" post="(PRNT50 = 1:320–1:5120). Among the 5 samples, 2 samples (Z472a and"/>
 <result pre="4-fold or greater level of neutralizing antibodies to all 4" exact="DENV" post="serotypes (Table 2). In addition, by testing all 879"/>
 <result pre="both rounds using PRNT, 13 participants (1.6%, N = 801) had detectable" exact="ZIKV" post="neutralizing antibodies. Overall, 7 participants (0.9%, Z140, Z141, Z153,"/>
 <result pre="(0.9%, Z140, Z141, Z153, Z476, Z735, Z472 and Z606) demonstrated" exact="ZIKV" post="neutralizing antibody titers that were at least 4-fold higher"/>
 <result pre="least 4-fold higher than their antibody titers to all 4" exact="DENV" post="serotypes, whereas the other 6 participants (0.8%) demonstrated comparable"/>
 <result pre="whereas the other 6 participants (0.8%) demonstrated comparable levels of" exact="ZIKV" post="and DENV neutralizing antibodies. Thus, the results suggest that"/>
 <result pre="other 6 participants (0.8%) demonstrated comparable levels of ZIKV and" exact="DENV" post="neutralizing antibodies. Thus, the results suggest that the 7"/>
 <result pre="results suggest that the 7 participants had been exposed to" exact="ZIKV" post="during the 2016 ZIKV epidemic. Anti-Zika virus NS1 immunoglobulin"/>
 <result pre="7 participants had been exposed to ZIKV during the 2016" exact="ZIKV" post="epidemic. Anti-Zika virus NS1 immunoglobulin G levels in cases"/>
 <result pre="Anti-Zika virus NS1 immunoglobulin G levels in cases of probable" exact="Zika" post="virus infection Levels of anti-ZIKV NS1 IgG antibodies in"/>
 <result pre="that exhibited anti-ZIKV IgM antibodies and five samples that demonstrated" exact="ZIKV" post="neutralizing antibodies but negative for anti-ZIKV IgM antibodies (N = 88)"/>
 <result pre="(R&amp;amp;D Systems). Anti-ZIKV NS1 IgG assays are useful for confirming" exact="ZIKV" post="infection because they are highly specific and possess minimal"/>
 <result pre="minimal cross-reactivity to other flaviviruses [38]. Sixteen out of 83" exact="ZIKV" post="IgM positive samples (19.3%) demonstrated ZIKV NS1 specific IgG"/>
 <result pre="Sixteen out of 83 ZIKV IgM positive samples (19.3%) demonstrated" exact="ZIKV" post="NS1 specific IgG antibodies, with a mean of P/N"/>
 <result pre="ratio of 5.7 ± 10.3 (data not shown). Among 8 of 83" exact="ZIKV" post="IgM positive samples that demonstrated neutralizing antibodies to ZIKV,"/>
 <result pre="and Z735a) that demonstrated a 4-fold or greater ratio of" exact="ZIKV" post="neutralizing antibody titers to DENV antibody titers also demonstrated"/>
 <result pre="4-fold or greater ratio of ZIKV neutralizing antibody titers to" exact="DENV" post="antibody titers also demonstrated ZIKV NS1 IgG antibodies (P/N"/>
 <result pre="ZIKV neutralizing antibody titers to DENV antibody titers also demonstrated" exact="ZIKV" post="NS1 IgG antibodies (P/N ratio = 3.1–8.1). These results confirm that"/>
 <result pre="These results confirm that these 3 participants were exposed to" exact="ZIKV" post="infection. Three of the 5 samples (Z120a, Z138a, Z140a,"/>
 <result pre="of the 5 samples (Z120a, Z138a, Z140a, Z420a, Z476a) with" exact="ZIKV" post="neutralizing antibodies were also confirmed positive for anti-ZIKV NS1"/>
 <result pre="5 samples (Z147, Z472, Z587, Z591 and Z606) that demonstrated" exact="ZIKV" post="neutralizing antibodies (N = 718, ZIKV IgM negative samples) were also"/>
 <result pre="Z587, Z591 and Z606) that demonstrated ZIKV neutralizing antibodies (N = 718," exact="ZIKV" post="IgM negative samples) were also positive for anti-ZIKV NS1"/>
 <result pre="antibodies. Two samples (Z472 and Z606) were positive for both" exact="ZIKV" post="neutralizing antibodies and ZIKV NS1 IgG (P/N ratio = 10.6 and"/>
 <result pre="and Z606) were positive for both ZIKV neutralizing antibodies and" exact="ZIKV" post="NS1 IgG (P/N ratio = 10.6 and 46.1 respectively). In addition,"/>
 <result pre="exhibited anti-ZIKV IgM antibodies positive and three samples that showed" exact="ZIKV" post="neutralizing antibodies but negative for anti-ZIKV IgM antibodies (Table"/>
 <result pre="Z476, Z735, Z147, Z472 and Z606) exhibited neutralizing antibodies against" exact="ZIKV" post="with PRNT50 titers ≥1:20. In summary, out of 801"/>
 <result pre="Z140, Z141, Z147, Z153, Z735, Z476, Z472 and Z606) had" exact="ZIKV" post="infection. Of these 9 participants, 5 (Z120, Z140, Z141,"/>
 <result pre="her immediate family members has been confirmed confirmed positive for" exact="ZIKV" post="infection in the Cu Pong commune in 2016 [25]."/>
 <result pre="cases in Pong Drang village (0.99%) (Fig. 2). Fig. 2" exact="Zika" post="virus (ZIKV) antibody seroprevalence in the survey districts, Dak"/>
 <result pre="seroprevalence in the survey districts, Dak Lak Province, Central Vietnam." exact="Zika" post="virus seroprevalence was determined by testing serum samples of"/>
 <result pre="seroprevalence was determined by testing serum samples of residents for" exact="ZIKV" post="anti-NS1 IgG antibodies by using an enzyme-linked immunosorbent assay"/>
 <result pre="indicates villages in which all study participants tested negative for" exact="ZIKV" post="antibodies. N indicates the number of residents who were"/>
 <result pre="N indicates the number of residents who were tested for" exact="ZIKV" post="antibodies, and percentage of confirmed cases were indicated in"/>
 <result pre="and IgG antibodies among 801 participants who were recruited during" exact="ZIKV" post="epidemic in Vietnam. Of the 83 first samples that"/>
 <result pre="epidemic in Vietnam. Of the 83 first samples that demonstrated" exact="ZIKV" post="IgM antibodies, only 8 (1.0%) had ZIKV neutralizing antibodies"/>
 <result pre="samples that demonstrated ZIKV IgM antibodies, only 8 (1.0%) had" exact="ZIKV" post="neutralizing antibodies (PRNT = 1:40–1:640) with 3 cases exposed to ZIKV"/>
 <result pre="had ZIKV neutralizing antibodies (PRNT = 1:40–1:640) with 3 cases exposed to" exact="ZIKV" post="infection confirmed using PRNT50 with ZIKV neutralizing titer ≥4fold"/>
 <result pre="3 cases exposed to ZIKV infection confirmed using PRNT50 with" exact="ZIKV" post="neutralizing titer ≥4fold of DENVs neutralizing titer. While anti-IgM"/>
 <result pre="ZIKV neutralizing titer ≥4fold of DENVs neutralizing titer. While anti-IgM" exact="ZIKV" post="antibodies may have lower specificity than other laboratory assays,"/>
 <result pre="other laboratory assays, the test is useful for identifying probable" exact="ZIKV" post="cases during an outbreak [32, 39]. Due to relatively"/>
 <result pre="outbreak [32, 39]. Due to relatively short detection window for" exact="ZIKV" post="IgM antibodies, a combination of tests that determine ZIKV"/>
 <result pre="for ZIKV IgM antibodies, a combination of tests that determine" exact="ZIKV" post="neutralizing antibodies and ZIKV-specific IgG antibodies would be useful"/>
 <result pre="antibodies would be useful for long-term seroprevelance studies. As such," exact="ZIKV" post="IgM test was used to determine ZIKV IgM antibodies"/>
 <result pre="studies. As such, ZIKV IgM test was used to determine" exact="ZIKV" post="IgM antibodies during the ZIKV outbreak in Vietnam in"/>
 <result pre="test was used to determine ZIKV IgM antibodies during the" exact="ZIKV" post="outbreak in Vietnam in 2016, and ZIKV-specific IgG ELISA"/>
 <result pre="NS1 IgG assays in all 83 participants that demonstrated cross-reactive" exact="ZIKV" post="IgM antibodies, only 6 (7.2%) samples fulfilled the criteria"/>
 <result pre="IgM antibodies, only 6 (7.2%) samples fulfilled the criteria of" exact="ZIKV" post="PRNT ratio &amp;gt; 4 and presence of ZIKV-specific NS1 cross-reactive antibodies,"/>
 <result pre="Among these 6 confirmed cases, 3 samples that were only" exact="ZIKV" post="NS1 IgG antibodies positive during the first collection also"/>
 <result pre="IgG antibodies positive during the first collection also demonstrated high" exact="ZIKV" post="neutralization titers 18 months later. None of the ZIKV seropositive"/>
 <result pre="demonstrated high ZIKV neutralization titers 18 months later. None of the" exact="ZIKV" post="seropositive participants had an international travel history, suggesting that"/>
 <result pre="seropositivity rates across age groups, indicating that the risk of" exact="ZIKV" post="infection is homologous across different age groups. In contrast,"/>
 <result pre="age groups. In contrast, a high proportion of participants demonstrated" exact="DENV" post="IgG antibodies, with seropositivity increasing with age [37, 40,"/>
 <result pre="other studies, indicating association with longer exposure due to persistent" exact="DENV" post="endemicity. While there were high levels of DENV seropositivity"/>
 <result pre="to persistent DENV endemicity. While there were high levels of" exact="DENV" post="seropositivity (49/83; 59.0%), indicating DENV exposure in the community,"/>
 <result pre="there were high levels of DENV seropositivity (49/83; 59.0%), indicating" exact="DENV" post="exposure in the community, the overall seropositive rates for"/>
 <result pre="DENV exposure in the community, the overall seropositive rates for" exact="ZIKV" post="remains low (9/801; 1.1%). While low ZIKV seroprevalence, a"/>
 <result pre="seropositive rates for ZIKV remains low (9/801; 1.1%). While low" exact="ZIKV" post="seroprevalence, a proxy of protection, indicates vulnerability of the"/>
 <result pre="indicates vulnerability of the population of the region to the" exact="ZIKV" post="epidemic, the results also suggest that DENV may offer"/>
 <result pre="region to the ZIKV epidemic, the results also suggest that" exact="DENV" post="may offer limited cross-protection against ZIKV. Among the participants,"/>
 <result pre="ZIKV. Among the participants, there was no significant difference in" exact="ZIKV" post="IgM seroprevalence according to sex. The higher percentage of"/>
 <result pre="opportunities in urban areas. While statistically insignificant, the proportion of" exact="ZIKV" post="IgM seropositivity in the Kinh ethnic group was higher"/>
 <result pre="the region, these factors may in turn lead to further" exact="Zika" post="epidemic expansion during outbreaks. Of the 718 samples that"/>
 <result pre="during outbreaks. Of the 718 samples that were negative for" exact="ZIKV" post="IgM antibodies, 5 samples demonstrated high levels of ZIKV"/>
 <result pre="for ZIKV IgM antibodies, 5 samples demonstrated high levels of" exact="ZIKV" post="neutralizing antibodies with titers from 1: 320–1: 5120. Additionally,"/>
 <result pre="with neutralizing antibody titers of 1:1280–1:5120. These results indicate local" exact="ZIKV" post="transmission within the healthy community in the Central Highlands"/>
 <result pre="the Central Highlands of Vietnam. Overall, 9/801 (1.1%) of the" exact="ZIKV" post="confirmed case as positive for ZIKV had 5/200 (2.5%)"/>
 <result pre="9/801 (1.1%) of the ZIKV confirmed case as positive for" exact="ZIKV" post="had 5/200 (2.5%) cases collected in Cu Pong village,"/>
 <result pre="were identified, respectively. This result indicates that the circulation of" exact="ZIKV" post="in Central Vietnam is limited in the period of"/>
 <result pre="in the period of 2 years since the confirmation of nationwide" exact="ZIKV" post="outbreak in Vietnam. In comparison with previous reports in"/>
 <result pre="in Vietnam. In comparison with previous reports in Indochina, the" exact="ZIKV" post="seroprevalence found in this study is at comparable levels"/>
 <result pre="with those of Cambodia [42] and Laos [43]. The low" exact="ZIKV" post="seroprevalence, a proxy of protection against the disease in"/>
 <result pre="however indicates that the community is at risk of subsequent" exact="ZIKV" post="epidemic. Conclusion This study confirms ZIKV infection in the"/>
 <result pre="at risk of subsequent ZIKV epidemic. Conclusion This study confirms" exact="ZIKV" post="infection in the Central Highlands of Vietnam and suggests"/>
 <result pre="infection in the Central Highlands of Vietnam and suggests that" exact="ZIKV" post="has been present in the province since at least"/>
 <result pre="may play a role in introducing emerging pathogens such as" exact="ZIKV" post="to rural areas. While DENV seroprevalence remains high in"/>
 <result pre="introducing emerging pathogens such as ZIKV to rural areas. While" exact="DENV" post="seroprevalence remains high in the region, the overall low"/>
 <result pre="DENV seroprevalence remains high in the region, the overall low" exact="ZIKV" post="seroprevalence indicate limited Zika disease protection in the population."/>
 <result pre="in the region, the overall low ZIKV seroprevalence indicate limited" exact="Zika" post="disease protection in the population. Further studies of seroprevalence"/>
 <result pre="the general population and to define the potential risk of" exact="ZIKV" post="transmission in the region. Abbreviations DENV Dengue virus ELISA"/>
 <result pre="the potential risk of ZIKV transmission in the region. Abbreviations" exact="DENV" post="Dengue virus ELISA Enzyme-linked immunosorbent assay IgG Immunoglobulin G"/>
 <result pre="potential risk of ZIKV transmission in the region. Abbreviations DENV" exact="Dengue" post="virus ELISA Enzyme-linked immunosorbent assay IgG Immunoglobulin G IgM"/>
 <result pre="IgG Immunoglobulin G IgM Immunoglobulin M PRNT Plaque-reduction neutralization test" exact="ZIKV" post="Zika virus Publisher’s Note Springer Nature remains neutral with"/>
 <result pre="Immunoglobulin G IgM Immunoglobulin M PRNT Plaque-reduction neutralization test ZIKV" exact="Zika" post="virus Publisher’s Note Springer Nature remains neutral with regard"/>
 <result pre="of the Genus Flavivirus1998 3.BoyerSCalvezEChouin-CarneiroTDialloDFaillouxA-BAn overview of mosquito vectors of" exact="Zika" post="virusMicrobes Infect20182064666010.1016/J.MICINF.2018.01.00629481868 4.ZamaniMZamaniVSexual transmission of Zika virus: an assessment"/>
 <result pre="of mosquito vectors of Zika virusMicrobes Infect20182064666010.1016/J.MICINF.2018.01.00629481868 4.ZamaniMZamaniVSexual transmission of" exact="Zika" post="virus: an assessment of the evidenceIran J Public Health2017461305130629026802"/>
 <result pre="of MicronesiaN Engl J Med20093602536254310.1056/NEJMoa080571519516034 6.KandelNLamichhaneJTangermannRHRodierGRDetecting Guillain-Barré syndrome caused by" exact="Zika" post="virus using systems developed for polio surveillanceBull World Health"/>
 <result pre="polio surveillanceBull World Health Organ20169470570810.2471/BLT.16.17150427708476 7.TeixeiraMGda CNCMde OliveiraWKNunesMLRodriguesLCThe Epidemic of" exact="Zika" post="Virus-Related Microcephaly in Brazil: Detection, Control, Etiology, and Future"/>
 <result pre="Future ScenariosAm J Public Health201610660160510.2105/AJPH.2016.30311326959259 8.BesnardMLastèreSTeissierACao-LormeauVMussoDEvidence of perinatal transmission of" exact="Zika" post="virus, French Polynesia, December 2013 and February 2014Eurosurveillance.2014192075110.2807/1560-7917.ES2014.19.13.2075124721538 9.MussoDNillesEJCao-LormeauV-MRapid"/>
 <result pre="Polynesia, December 2013 and February 2014Eurosurveillance.2014192075110.2807/1560-7917.ES2014.19.13.2075124721538 9.MussoDNillesEJCao-LormeauV-MRapid spread of emerging" exact="Zika" post="virus in the Pacific areaClin Microbiol Infect201420O595O59610.1111/1469-0691.1270724909208 10.PetersenLRJamiesonDJPowersAMHoneinMAZika VirusN"/>
 <result pre="areaClin Microbiol Infect201420O595O59610.1111/1469-0691.1270724909208 10.PetersenLRJamiesonDJPowersAMHoneinMAZika VirusN Engl J Med20163741552156310.1056/NEJMra160211327028561 11.WHO |" exact="Zika" post="epidemiology update. WHO. 2019. https://www.who.int/emergencies/diseases/zika/epidemiology-update/en/. Accessed 14 Oct 2019."/>
 <result pre="2019. https://www.who.int/emergencies/diseases/zika/epidemiology-update/en/. Accessed 14 Oct 2019. 12.WiwanitkitVThe current status of" exact="Zika" post="virus in Southeast AsiaEpidemiol Health201638e201602610.4178/epih.e201602627336445 13.OlsonJGKsiazekTGSuhandimanTZika virus, a cause"/>
 <result pre="Java, IndonesiaTrans R Soc Trop Med Hyg19817538939310.1016/0035-9203(81)90100-06275577 14.HoZJMHapuarachchiHCBarkhamTChowANgLCLeeJMVet al.Outbreak of" exact="Zika" post="virus infection in Singapore: an epidemiological, entomological, virological, and"/>
 <result pre="virological, and clinical analysisLancet Infect Dis20171781382110.1016/S1473-3099(17)30249-928527892 15.RuchusatsawatKWongjaroenPPosanacharoenARodriguez-BarraquerISangkitpornSCummingsDATet al.Long-term circulation of" exact="Zika" post="virus in Thailand: an observational studyLancet Infect Dis20191943944610.1016/S1473-3099(18)30718-730826189 16.WoonYLLimMFTg"/>
 <result pre="Infect Dis20191915210.1186/s12879-019-3786-930760239 17.Myat Ngwe TunMKyaw KyawAWut HmoneSInoueSBueranoCCMin SoeAet al.Detection of" exact="Zika" post="Virus Infection in MyanmarAm J Trop Med Hyg201898SS10.4269/ajtmh.17-0708 18.MeltzerELustigYLeshemELevyRGottesmanGWeissmannRet"/>
 <result pre="Tajima S, Takaya S, Yamamoto K, et al. Detection of" exact="Zika" post="virus in a traveller from Vietnam to Japan. J"/>
 <result pre="to Japan. J Travel Med. 2017;24. 10.1093/jtm/tax031. 20.LimSKLimJKYoonIKAn Update on" exact="Zika" post="Virus in AsiaInfect Chemother2017499110010.3947/ic.2017.49.2.9128681575 21.HashimotoTKutsunaSTajimaSNakayamaEMaekiTTaniguchiSet al.Importation of Zika virus"/>
 <result pre="Update on Zika Virus in AsiaInfect Chemother2017499110010.3947/ic.2017.49.2.9128681575 21.HashimotoTKutsunaSTajimaSNakayamaEMaekiTTaniguchiSet al.Importation of" exact="Zika" post="virus from Vietnam to Japan, November 2016Emerg Infect Dis201723122310.3201/EID2307.17051928445122"/>
 <result pre="VTQ, Thuong NV, Hung PC, Huong TTLN, et al. Fetal" exact="Zika" post="virus infection in Vietnam. PLoS Curr. 2017;9. 10.1371/currents.outbreaks.1c8f631e0ef8cd7777d639eba48647fa. 23.QuyenNTHKienDTHRabaaMTuanNMViTTVan"/>
 <result pre="in Vietnam. PLoS Curr. 2017;9. 10.1371/currents.outbreaks.1c8f631e0ef8cd7777d639eba48647fa. 23.QuyenNTHKienDTHRabaaMTuanNMViTTVan TanLet al.Chikungunya and" exact="Zika" post="virus cases detected against a backdrop of endemic dengue"/>
 <result pre="Heal20051037938610.1111/j.1365-3156.2005.01388.x 29.MussoDGublerDJZika VirusClin Microbiol Rev20162948752410.1128/CMR.00072-1527029595 30.OliveiraRAde Oliveira-FilhoEFFernandesAIBritoCAMarquesETTenórioMCet al.Previous dengue or" exact="Zika" post="virus exposure can drive to infection enhancement or neutralisation"/>
 <result pre="Oswaldo Cruz201911417 31.Heinz FX, Stiasny K. The antigenic structure of" exact="Zika" post="virus and its relation to other Flaviviruses: implications for"/>
 <result pre="Biol Rev. 2017;81. 10.1128/MMBR.00055-16. 32.WijesooriyaSLNguyenCTNguyenTTTVuTBHTaichiroTMoritaKet al.Long-term surveillance needed to detect" exact="Zika" post="virus outbreaks in endemic regionsLancet Infect Dis20202016816910.1016/S1473-3099(19)30677-232006504 33.PourhoseingholiMAVahediMRahimzadehMSample size"/>
 <result pre="in medical studiesGastroenterol Hepatol from bed to bench201361417 34.Focus Diagnostics." exact="Dengue" post="Virus IgM Capture DxSelect TM (OUS). http://www.focusdx.com/pdfs/pi/OUS/EL1500M-OUS.pdf. Accessed 28"/>
 <result pre="ZIK00. https://www.rndsystems.com/products/human-anti-zika-virus-igg-elisa-kit_zik00. Accessed 3 Feb 2020. 39.WHO. Laboratory testing for" exact="Zika" post="virus infection. World Heal Organ. 2016;1. 10.1038/sj.mp.4001048. 40.Van LeTThi"/>
 <result pre="(2010- 2015)Am J Epidemiol Infect Dis20175813 42.DuongVOngSLeangRHuyRLySMounierUet al.Low circulation of" exact="Zika" post="virus, Cambodia, 2007-2016Emerg Infect Dis20172329629910.3201/eid2302.16143227875110 43.PastorinoBSengvilaipaseuthOChanthongthipAVongsouvathMSouksakhoneCMayxayMet al.Low Zika virus"/>
 <result pre="circulation of Zika virus, Cambodia, 2007-2016Emerg Infect Dis20172329629910.3201/eid2302.16143227875110 43.PastorinoBSengvilaipaseuthOChanthongthipAVongsouvathMSouksakhoneCMayxayMet al.Low" exact="Zika" post="virus Seroprevalence in Vientiane, Laos, 2003-2015Am J Trop Med"/>
</results>
